USFDA approves Pfizer’s marstacimab-hncq for treatment of hemophilia A or B
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
We now rank 3rd in pharmaceutical production by volume and 14th by value
Biotin Sublingual Spray and Melatonin Sublingual Spray to help consumers tackle health issues that come with today’s fast-paced life
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Strategic focus on COCO-model with a nationwide reach of 501 stores
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
Subscribe To Our Newsletter & Stay Updated